|
|
三阴性乳腺癌的耐药机制及与DLG5的研究进展
|
Abstract:
三阴性乳腺癌(Triple Negative Breast Cancer, TNBC)是乳腺癌的一种特定亚型，因其不表达雌激素受体 (Estrogen Receptor, ER)、孕酮受体(Progesterone Receptor, PR)或人表皮生长因子受体-2 (Epi-dermal Growth Factor Receptor, HER-2)具有高侵袭能力，预后较其他类型乳腺癌差，在治疗上往往因为出现耐药性导致癌症进展和复发。早期应用化疗药物对三阴性乳腺癌有明显治疗效果，但随着化疗药物的应用，患者可逐渐出现耐药，导致总体生存率低下。因此，研究三阴性乳腺癌的化疗耐药性是目前乳腺癌的关注热点。本文回顾了三阴性乳腺癌耐药的研究进展，特别是极性蛋白DLG5在三阴性乳腺癌耐药中的作用以及影响，以期为临床治疗提供参考。
Triple negative breast cancer (TNBC) is a specific subtype of breast cancer because it does not ex-press estrogen receptor (ER), progesterone receptor (PR) or human epidermal growth factor re-ceptor (epidermal growth factor receptor, HER-2) has high aggressiveness, has a worse prognosis than other types of breast cancer, and is often treated because of drug resistance leading to cancer progression and recurrence. Early use of chemotherapy drugs has a significant therapeutic effect on triple-negative breast cancer, but with the application of chemotherapy drugs, patients can gradu-ally develop drug resistance, resulting in low overall survival. Therefore, the study of chemotherapy resistance in triple-negative breast cancer is currently a hot spot in breast cancer. This article re-views the research progress of triple-negative breast cancer drug resistance, especially the role and impact of polar protein DLG5 in triple-negative breast cancer drug resistance, in order to provide reference for clinical treatment.
| [1] | Waks, A.G. and Winer, E.P. (2019) Breast Cancer Treatment: A Review. JAMA, 321, 288-300.
https://doi.org/10.1001/jama.2018.19323 |
| [2] | Bianchini, G., de Angelis, C. and Licata, L. (2022) Treatment Land-scape of Triple-Negative Breast Cancer—Expanded Options, Evolving Needs. Nature Reviews Clinical Oncology, 19, 91-113. https://doi.org/10.1038/s41571-021-00565-2 |
| [3] | Yin, L., Duan, J.J. and Bian, X.W. (2020) Tri-ple-Negative Breast Cancer Molecular Subtyping and Treatment Progress. Breast Cancer Research: BCR, 22, Article No. 61. https://doi.org/10.1186/s13058-020-01296-5 |
| [4] | Derakhshan, F. and Reis-Filho, J.S. (2022) Pathogenesis of Triple-Negative Breast Cancer. Annual Review of Pathology: Mechanisms of Disease, 17, 181-204. https://doi.org/10.1146/annurev-pathol-042420-093238 |
| [5] | Won, K. and Spruck, C. (2020) Triple-Negative Breast Cancer Therapy: Current and Future Perspectives (Review). International Journal of Oncology, 57, 1245-1261. https://doi.org/10.3892/ijo.2020.5135 |
| [6] | Liedtke, C., Mazouni, C. and Hess, K.R. (2008) Response to Neoadju-vant Therapy and Long-Term Survival in Patients with Triple-Negative Breast Cancer. Journal of Clinical Oncology: Of-ficial Journal of the American Society of Clinical Oncology, 26, 1275-1281. https://doi.org/10.1200/JCO.2007.14.4147 |
| [7] | Kumar, P. and Aggarwal, R. (2016) An Overview of Tri-ple-Negative Breast Cancer. Archives of Gynecology and Obstetrics, 293, 247-269. https://doi.org/10.1007/s00404-015-3859-y |
| [8] | Loibl, S., Poortmans, P. and Morrow, M. (2021) Breast Cancer. The Lancet (London, England), 397, 1750-1769.
https://doi.org/10.1016/S0140-6736(20)32381-3 |
| [9] | Early Breast Cancer Trialists’ Collaborative Group, et al. (2012) Comparisons between Different Polychemotherapy Regimens for Early Breast Cancer: Meta-Analyses of Long-Term Outcome among 100,000 Women in 123 Randomised Trials. The Lancet, 379, 432-444. https://pubmed.ncbi.nlm.nih.gov/22152853/ |
| [10] | Blum, J.L., Flynn, P.J., Yothers, G., et al. (2023) Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG On-cology). Journal of Clinical Oncology, 35, 2647-2655. https://pubmed.ncbi.nlm.nih.gov/28398846/ |
| [11] | Nitz, U., Gluz, O. and Clemens, M. (2019) West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophos-phamide plus Docetaxel versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 37, 799-808. https://doi.org/10.1200/JCO.18.00028 |
| [12] | Poggio, F., Bruzzone, M. and Ceppi, M. (2018) Platinum-Based Neo-adjuvant Chemotherapy in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 29, 1497-1508. https://doi.org/10.1093/annonc/mdy127 |
| [13] | Von Minckwitz, G., Schneeweiss, A. and Loibl, S. (2014) Neoadju-vant Carboplatin in Patients with Triple-Negative and HER2-Positive Early Breast Cancer (GeparSixto; GBG 66): A Randomised Phase 2 Trial. The Lancet Oncology, 15, 747-756. https://doi.org/10.1016/S1470-2045(14)70160-3 |
| [14] | Sikov, W.M., Berry, D.A. and Perou, C.M. (2015) Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 33, 13-21. |
| [15] | Zhu, Y., Hu, Y. and Tang, C. (2022) Platinum-Based Systematic Therapy in Triple-Negative Breast Cancer. Biochimica et Biophysica Acta. Reviews on Cancer, 1877, Article ID: 188678. https://doi.org/10.1016/j.bbcan.2022.188678 |
| [16] | Wang, X.L., Chen, T., Li, C., et al. (2022) CircRNA-CREIT In-hibits Stress Granule Assembly and Overcomes Doxorubicin Resistance in TNBC by Destabilizing PKR. Journal of Hematology & Oncology, 15, 122.
https://pubmed.ncbi.nlm.nih.gov/36038948/ |
| [17] | Nedeljkovi？, M. and Damjanovi？, A. (2019) Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge. Cells, 8, Article No. 957. https://doi.org/10.3390/cells8090957 |
| [18] | Sissung, T.M., Baum, C.E., Kirkland, C.T., et al. (2010) Phar-macogenetics of Membrane Transporters: An Update on Current Approaches. Molecular Biotechnology, 44, 152-167. https://pubmed.ncbi.nlm.nih.gov/19950006/ |
| [19] | Sharom, F.J. (2008) ABC Multidrug Transporters: Structure, Function and Role in Chemoresistance. Pharmacogenomics, 9, 105-127. https://doi.org/10.2217/14622416.9.1.105 |
| [20] | Yamada, A., Ishikawa, T. and Ota, I. (2013) High Expression of ATP-Binding Cassette Transporter ABCC11 in Breast Tumors Is Associated with Aggressive Subtypes and Low Dis-ease-Free Survival. Breast Cancer Research and Treatment, 137, 773-782. https://doi.org/10.1007/s10549-012-2398-5 |
| [21] | Guestini, F., Ono, K. and Miyashita, M. (2019) Impact of Topoi-somerase IIα, PTEN, ABCC1/MRP1, and KI67 on Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Breast Cancer Research and Treatment, 173, 275-288. https://doi.org/10.1007/s10549-018-4985-6 |
| [22] | Das, S., Samant, R.S. and Shevde, L.A. (2013) Nonclassical Ac-tivation of Hedgehog Signaling Enhances Multidrug Resistance and Makes Cancer Cells Refractory to Smooth-ened-Targeting Hedgehog Inhibition. The Journal of Biological Chemistry, 288, 11824-11833. https://doi.org/10.1074/jbc.M112.432302 |
| [23] | Skoda, A.M., Simovic, D. and Karin, V. (2018) The Role of the Hedgehog Signaling Pathway in Cancer: A Comprehensive Review. Bosnian Journal of Basic Medical Sciences, 18, 8-20. https://doi.org/10.17305/bjbms.2018.2756 |
| [24] | Harris, L.G., Pannell, L.K. and Singh, S. (2012) Increased Vascularity and Spontaneous Metastasis of Breast Cancer by Hedgehog Signaling Mediated Upregulation of cyr61. On-cogene, 31, 3370-3380. https://doi.org/10.1038/onc.2011.496 |
| [25] | Kwon, Y.-J., Hurst, D.R., Steg, A.D., et al. (2011) Gli1 Enhances Migration and Invasion via Up-Regulation of MMP-11 and Promotes Metastasis in ERα Negative Breast Cancer Cell Lines. Clinical & Experimental Metastasis, 28, 437-449. https://pubmed.ncbi.nlm.nih.gov/21442356/ |
| [26] | Di Mauro, C., Rosa, R. and D’amato, V. (2017) Hedgehog Sig-nalling Pathway Orchestrates Angiogenesis in Triple-Negative Breast Cancers. British Journal of Cancer, 116, 1425-1435. https://doi.org/10.1038/bjc.2017.116 |
| [27] | Shibata, M. and Hoque, M.O. (2019) Targeting Cancer Stem Cells: A Strategy for Effective Eradication of Cancer. Cancers, 11, Article No. 732. https://doi.org/10.3390/cancers11050732 |
| [28] | Creighton, C.J., Li, X. and Landis, M. (2009) Residual Breast Can-cers after Conventional Therapy Display Mesenchymal as Well as Tumor-Initiating Features. Proceedings of the National Academy of Sciences of the United States of America, 106, 13820-13825. https://doi.org/10.1073/pnas.0905718106 |
| [29] | Lee, H.E., Kim, J.H. and Kim, Y.J. (2011) An Increase in Cancer Stem Cell Population after Primary Systemic Therapy Is a Poor Prognostic Factor in Breast Cancer. British Journal of Cancer, 104, 1730-1738.
https://doi.org/10.1038/bjc.2011.159 |
| [30] | Park, S.Y., Lee, H.E., Li, H.L., et al. (2010) Heterogeneity for Stem Cell-Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer. Clinical Cancer Research, 16, 876-887.
https://pubmed.ncbi.nlm.nih.gov/20103682/ |
| [31] | Ma, F., Li, H.H., Wang, H.J., et al. (2014) Enriched CD44(+)/CD24(？) Population Drives the Aggressive Phenotypes Presented in Triple-Negative Breast Cancer (TNBC). Cancer Letters, 353, 153-159.
https://pubmed.ncbi.nlm.nih.gov/25130168/ |
| [32] | Zhou, S., Schuetz, J.D., Bunting, K.D., et al. (2001) The ABC Transporter Bcrp1/ABCG2 Is Expressed in a Wide Variety of Stem Cells and Is a Molecular Determinant of the Side-Population Phenotype. Nature Medicine, 7, 1028-1034.
https://pubmed.ncbi.nlm.nih.gov/11533706/ |
| [33] | Vaupel, P. (2008) Hypoxia and Aggressive Tumor Phenotype: Implications for Therapy and Prognosis. The Oncologist, 13, 21-26. https://doi.org/10.1634/theoncologist.13-S3-21 |
| [34] | Gerweck, L.E., Vijayappa, S. and Kozin, S. (2006) Tumor pH Controls the in Vivo Efficacy of Weak Acid and Base Chemotherapeutics. Molecular Cancer Therapeutics, 5, 1275-1279. https://pubmed.ncbi.nlm.nih.gov/16731760/ |
| [35] | Cosse, J.P. and Michiels, C. (2008) Tumour Hypoxia Affects the Responsiveness of Cancer Cells to Chemotherapy and Promotes Cancer Progression. Anti-Cancer Agents in Medicinal Chemistry, 8, 790-797.
https://doi.org/10.2174/187152008785914798 |
| [36] | Kim, H., Lin, Q., Glazer, P.M. and Yun, Z. (2018) The Hy-poxic Tumor Microenvironment in Vivo Selects the Cancer Stem Cell Fate of Breast Cancer Cells. Breast Cancer Re-search, 20, 16. https://pubmed.ncbi.nlm.nih.gov/29510720/ |
| [37] | Chouaib, S., Noman, M.Z. and Kosmatopoulos, K. (2017) Hypoxic Stress: Obstacles and Opportunities for Innovative Immunotherapy of Cancer. Oncogene, 36, 439-445. https://doi.org/10.1038/onc.2016.225 |
| [38] | Xiang, L., Liu, Z.-H., Huan, Q., et al. (2012) Hypox-ia-Inducible Factor-2a Is Associated with ABCG2 Expression, Histology-Grade and Ki67 Expression in Breast Invasive Ductal Carcinoma. Diagnostic Pathology, 7, 32.
https://pubmed.ncbi.nlm.nih.gov/22452996/ |
| [39] | Lv, Y., Zhao, S. and Han, J. (2015) Hypoxia-Inducible Factor-1α Induces Multidrug Resistance Protein in Colon Cancer. OncoTargets and Therapy, 8, 1941-1948. https://doi.org/10.2147/OTT.S82835 |
| [40] | Daskalaki, I., Gkikas, I. and Tavernarakis, N. (2018) Hypoxia and Selec-tive Autophagy in Cancer Development and Therapy. Frontiers in Cell and Developmental Biology, 6, Article No. 104. https://pubmed.ncbi.nlm.nih.gov/30250843/ |
| [41] | Livasy, C.A., Karaca, G. and Nanda, R. (2006) Phenotypic Eval-uation of the Basal-Like Subtype of Invasive Breast Carcinoma. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc, 19, 264-271. https://doi.org/10.1038/modpathol.3800528 |
| [42] | Tan, E.Y., Yan, M. and Campo, L. (2009) The Key Hypoxia Reg-ulated Gene CAIX Is Upregulated in Basal-Like Breast Tumours and Is Associated with Resistance to Chemotherapy. British Journal of Cancer, 100, 405-411.
https://doi.org/10.1038/sj.bjc.6604844 |
| [43] | Chen, X., Iliopoulos, D., Zhang, Q., et al. (2014) XBP1 Promotes Tri-ple-Negative Breast Cancer by Controlling the HIF1α Pathway. Nature, 508, 103-107. https://pubmed.ncbi.nlm.nih.gov/24670641/ |
| [44] | Lei, J., Fan, L. and Wei, G. (2015) Gli-1 Is Crucial for Hypox-ia-Induced Epithelial-Mesenchymal Transition and Invasion of Breast Cancer. Tumour Biology: The Journal of the In-ternational Society for Oncodevelopmental Biology and Medicine, 36, 3119-3126. https://doi.org/10.1007/s13277-014-2948-z |
| [45] | Klionsky, D.J. and Emr, S.D. (2000) Autophagy as a Regulated Pathway of Cellular Degradation. Science (New York, N.Y.), 290, 1717-1721. https://doi.org/10.1126/science.290.5497.1717 |
| [46] | Chen, Y., Jia, Y. and Mao, M. (2021) PLAC8 Promotes Adriamycin Resistance via Blocking Autophagy in Breast Cancer. Journal of Cellular and Molecular Medicine, 25, 6948-6962. https://doi.org/10.1111/jcmm.16706 |
| [47] | Wang, L., Zhang, H. and Sun, M. (2015) High Mobility Group Box 1-Mediated Autophagy Promotes Neuroblastoma Cell Chemoresistance. Oncology Reports, 34, 2969-2976. https://doi.org/10.3892/or.2015.4278 |
| [48] | Yang, L., Yu, Y. and Kang, R. (2012) Up-Regulated Autophagy by En-dogenous High Mobility Group Box-1 Promotes Chemoresistance in Leukemia Cells. Leukemia & Lymphoma, 53, 315-322.
https://doi.org/10.3109/10428194.2011.616962 |
| [49] | Zhao, Y., Meng, Q. and Gao, X. (2017) Down-Regulation of Mediator Complex Subunit 19 (Med19) Induces Apoptosis in Human Laryngocarcinoma HEp2 Cells in an Apaf-1-Dependent Pathway. American Journal of Translational Research, 9, 755-761. |
| [50] | Liu, B., Qi, X. and Zhang, X. (2019) Med19 Is Involved in Chemoresistance by Mediating Autophagy through HMGB1 in Breast Cancer. Journal of Cellular Biochemistry, 120, 507-518. https://doi.org/10.1002/jcb.27406 |
| [51] | Ng, L.F., Kaur, P. and Bunnag, N. (2019) WNT Signaling in Disease. Cells, 8, 826.
https://doi.org/10.3390/cells8080826 |
| [52] | Duchartre, Y., Kim, Y.-M. and Kahn, M. (2016) The Wnt Signaling Pathway in Cancer. Critical Reviews in Oncology/Hematology, 99, 141-149. https://pubmed.ncbi.nlm.nih.gov/26775730/ |
| [53] | Liu, S., Wang, Z. and Liu, Z. (2018) miR-221/222 Activate the Wnt/β-Catenin Signaling to Promote Triple-Negative Breast Cancer. Journal of Molecular Cell Biology, 10, 302-315. https://doi.org/10.1093/jmcb/mjy041 |
| [54] | Xu, J.H., Prosperi, J.R., Choudhury, N., et al. (2015) β-Catenin Is Re-quired for the Tumorigenic Behavior of Triple-Negative Breast Cancer Cells. PLOS ONE, 10, e0117097. https://pubmed.ncbi.nlm.nih.gov/25658419/ |
| [55] | Vicens, Q. and Westhof, E. (2014) Biogenesis of Circular RNAs. Cell, 159, 13-14.
https://doi.org/10.1016/j.cell.2014.09.005 |
| [56] | Chen, C., Zhou, Z. and Sheehan, C.E. (2009) Overexpression of WWP1 Is Associated with the Estrogen Receptor and Insulin-Like Growth Factor Receptor 1 in Breast Carcinoma. In-ternational Journal of Cancer, 124, 2829-2836.
https://doi.org/10.1002/ijc.24266 |
| [57] | Lee, Y.R., Chen, M. and Lee, J.D. (2019) Reactivation of PTEN Tumor Suppressor for Cancer Treatment through Inhibition of a MYC-WWP1 Inhibitory Pathway. Science (New York, N.Y.), 364, eaau0159. |
| [58] | Nechiporuk, T., Fernandez, T.E. and Vasioukhin, V. (2007) Failure of Epithelial Tube Maintenance Causes Hydrocephalus and Renal Cysts in Dlg5-/-Mice. Developmental Cell, 13, 338-350. https://pubmed.ncbi.nlm.nih.gov/17765678/ |
| [59] | Sarrió, D., Rodriguez-Pinilla, S.M., et al. (2008) Epitheli-al-Mesenchymal Transition in Breast Cancer Relates to the Basal-Like Phenotype. Cancer Research, 68, 989-997. https://pubmed.ncbi.nlm.nih.gov/18281472/ |
| [60] | Liu, J., Li, J. and Li, P. (2017) Loss of DLG5 Promotes Breast Cancer Malignancy by Inhibiting the Hippo Signaling Pathway. Scientific Reports, 7, Article No. 42125. https://doi.org/10.1038/srep42125 |
| [61] | Qiao, X., Roth, I. and Féraille, E. (2014) Different Effects of ZO-1, ZO-2 and ZO-3 Silencing on Kidney Collecting Duct Principal Cell Proliferation and Adhesion. Cell Cycle (Georgetown, Tex.), 13, 3059-3075.
https://doi.org/10.4161/15384101.2014.949091 |
| [62] | Liu, J., Li, J. and Ren, Y. (2014) DLG5 in Cell Polarity Maintenance and Cancer Development. International Journal of Biological Sciences, 10, 543-549. https://doi.org/10.7150/ijbs.8888 |
| [63] | Caunt, C.J., Sale, M.J. and Smith, P.D. (2015) MEK1 and MEK2 Inhibitors and Cancer Therapy: The Long and Winding Road. Nature Reviews. Cancer, 15, 577-592. https://doi.org/10.1038/nrc4000 |
| [64] | Zhan, L., Rosenberg, A. and Bergami, K.C. (2008) Deregulation of Scribble Promotes Mammary Tumorigenesis and Reveals a Role for Cell Polarity in Carcinoma. Cell, 135, 865-878. https://doi.org/10.1016/j.cell.2008.09.045 |
| [65] | Martin-Belmonte, F. and Perez-Moreno, M. (2011) Epithelial Cell Polarity, Stem Cells and Cancer. Nature Reviews. Cancer, 12, 23-38. https://doi.org/10.1038/nrc3169 |
| [66] | Pan, D. (2010) The Hippo Signaling Pathway in Development and Cancer. Developmental Cell, 19, 491-505.
https://doi.org/10.1016/j.devcel.2010.09.011 |
| [67] | Zhao, B., Lei, Q.Y. and Guan, K.L. (2008) The Hippo-YAP Pathway: New Connections between Regulation of Organ Size and Cancer. Current Opinion in Cell Biology, 20, 638-646. https://doi.org/10.1016/j.ceb.2008.10.001 |
| [68] | Grzeschik, N.A., Parsons, L.M. and Allott, M.L. (2010) Lgl, aPKC, and Crumbs Regulate the Salvador/Warts/Hippo Pathway through Two Distinct Mechanisms. Current Biol-ogy: CB, 20, 573-581.
https://doi.org/10.1016/j.cub.2010.01.055 |
| [69] | Zhao, B., Wei, X.M., Li, W.Q., et al. (2007) Inactivation of YAP Oncoprotein by the Hippo Pathway Is Involved in Cell Contact Inhibition and Tissue Growth Control. Genes & Devel-opment, 21, 2747-2761.
https://pubmed.ncbi.nlm.nih.gov/17974916/ |
| [70] | Sezaki, T., Inada, K., Sogabe, T., et al. (2012) Role of Dlg5/lp-dlg, a Membrane-Associated Guanylate Kinase Family Protein, in Epithelial-Mesenchymal Transition in LLc-PK1 Renal Epithelial Cells. PLOS ONE, 7, e35519.
https://pubmed.ncbi.nlm.nih.gov/22539977/ |
| [71] | Neuzillet, C., Tijeras-Raballand, A. and Cohen, R. (2015) Tar-geting the TGFβ Pathway for Cancer Therapy. Pharmacology & Therapeutics, 147, 22-31. https://doi.org/10.1016/j.pharmthera.2014.11.001 |
| [72] | Asiedu, M.K., Ingle, J.N. and Behrens, M.D. (2011) TGF-beta/TNF(alpha)-Mediated Epithelial-Mesenchymal Transition Generates Breast Cancer Stem Cells with a Claudin-Low Phenotype. Cancer Research, 71, 4707-4719.
https://doi.org/10.1158/0008-5472.CAN-10-4554 |
| [73] | Brabletz, T., Kalluri, R. and Nieto, M.A. (2018) EMT in Cancer. Nature Reviews. Cancer, 18, 128-134.
https://doi.org/10.1038/nrc.2017.118 |
| [74] | Puisieux, A., Brabletz, T. and Caramel, J. (2014) Oncogenic Roles of EMT-Inducing Transcription Factors. Nature Cell Biology, 16, 488-494. https://pubmed.ncbi.nlm.nih.gov/24875735/ |
| [75] | Lamouille, S., Xu, J. and Derynck, R. (2014) Molecular Mecha-nisms of Epithelial-Mesenchymal Transition. Nature Reviews. Molecular Cell Biology, 15, 178-196. https://doi.org/10.1038/nrm3758 |
| [76] | Chen, B., Yuan, Y. and Sun, L. (2020) MKL1 Mediates TGF-β Induced RhoJ Transcription to Promote Breast Cancer Cell Migration and Invasion. Frontiers in Cell and Developmental Biology, 8, Article No. 832.
https://doi.org/10.3389/fcell.2020.00832 |
